{"nct_id":"NCT03689972","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","status":"COMPLETED","status_verified_date":"2024-05","start_date":"2018-11-27","start_date_type":"ACTUAL","primary_completion_date":"2023-01-31","primary_completion_date_type":"ACTUAL","completion_date":"2023-07-24","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BIIB"]}